Clinical aspects of platelet transfusions

Area of Science:

• Immunology
• Hematology
• Transfusion Medicine

Background:

• Platelet transfusion refractoriness is a significant complication, affecting up to 50% of patients undergoing repeated transfusions.
• Major causes include Human Leukocyte Antigen (HLA) alloimmunization and non-immune platelet consumption due to clinical factors like sepsis, DIC, and splenomegaly.
• Current management for alloimmunized patients involves HLA-matched platelet transfusions, which are effective in only about 65% of cases, highlighting the need for preventative strategies.

Purpose of the Study:

• To explore the mechanisms of HLA alloimmunization in platelet transfusion therapy.
• To evaluate the effectiveness of current management strategies for refractory patients.
• To investigate methods for the prevention of HLA alloimmunization to improve transfusion outcomes.

Main Methods:

• Review of existing literature on platelet transfusion refractoriness and HLA alloimmunization.
• Analysis of the role of leukocyte-depleted blood components in reducing alloimmunization.
• Discussion of novel techniques like UV irradiation for inactivating antigen-bearing cells.

Main Results:

• Primary HLA alloimmunization is linked to HLA class II antigen-bearing cells present in transfusions.
• Platelet concentrates express only HLA class I antigens, making pure platelets non-immunogenic.
• Leukocyte depletion of blood components has demonstrated a reduction in HLA alloimmunization and refractoriness.

Conclusions:

• Preventing HLA alloimmunization is crucial for effective platelet transfusion support.
• Leukocyte depletion of blood components is a viable strategy to reduce alloimmunization.
• Advanced techniques like UV irradiation offer promising avenues for preventing alloimmunization and improving transfusion outcomes.